Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Oct 27;29(7):1200–1208. doi: 10.1158/1078-0432.CCR-22-2145

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

©2022 The Authors; Published by the American Association for Cancer Research

This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.

PMC Copyright notice

Figure 2. Number of cycles of therapy for each of the evaluable 29 patients on the study based on their initial therapy cediranib (A) or sunitinib (B). Prior therapy is indicated next to patient ID: s = surgery; c = chemotherapy; r = radiation. Two patients achieved a PR in at least one arm of the study, before/and after crossover. C, Median PFS for all 34 patients based on initial therapy arm assignment. — Number of cycles of therapy for each of the evaluable 29 patients on the study based on their initial therapy: cediranib (A) or sunitinib (B). Prior therapy is indicated next to patient ID: s, surgery; c, chemotherapy; r, radiation. Two patients achieved a PR in at least one arm of the study, before/and after crossover. C, Median PFS for all 34 patients based on initial therapy arm assignment.